Clinical Trials | March 17, 2026
Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema
The company announced positive topline data from the Phase 3 ADorable-1 trial
The company announced positive topline data from the Phase 3 ADorable-1 trial
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The trial will enroll up to 42 patients in Finland across four cohorts
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
Subscribe To Our Newsletter & Stay Updated
